Cargando…

Comparison of (68)Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer

BACKGROUND: (18)F-NaF positron emission tomography/computed tomography (fluoride PET/CT) is considered the most sensitive technique to detect bone metastasis in prostate cancer (PCa). (68)Ga-PSMA-11 (PSMA) PET/CT is increasingly used for staging of PCa. This study primarily aimed to compare the diag...

Descripción completa

Detalles Bibliográficos
Autores principales: Regula, Naresh, Kostaras, Vasileios, Johansson, Silvia, Trampal, Carlos, Lindström, Elin, Lubberink, Mark, Iyer, Victor, Velikyan, Irina, Sörensen, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885936/
https://www.ncbi.nlm.nih.gov/pubmed/35229224
http://dx.doi.org/10.1186/s41824-022-00127-4
_version_ 1784660544712605696
author Regula, Naresh
Kostaras, Vasileios
Johansson, Silvia
Trampal, Carlos
Lindström, Elin
Lubberink, Mark
Iyer, Victor
Velikyan, Irina
Sörensen, Jens
author_facet Regula, Naresh
Kostaras, Vasileios
Johansson, Silvia
Trampal, Carlos
Lindström, Elin
Lubberink, Mark
Iyer, Victor
Velikyan, Irina
Sörensen, Jens
author_sort Regula, Naresh
collection PubMed
description BACKGROUND: (18)F-NaF positron emission tomography/computed tomography (fluoride PET/CT) is considered the most sensitive technique to detect bone metastasis in prostate cancer (PCa). (68)Ga-PSMA-11 (PSMA) PET/CT is increasingly used for staging of PCa. This study primarily aimed to compare the diagnostic performance of fluoride PET/CT and gallium-based PSMA PET/CT in identifying bone metastasis followed by a comparison of PSMA PET/CT with contrast-enhanced CT (CE-CT) in identifying soft tissue lesions as a secondary objective. METHODS: Twenty-eight PCa patients with high suspicion of disseminated disease following curative treatment were prospectively evaluated. PET/CT examinations using fluoride and PSMA were performed. All suspicious bone lesions were counted, and the tracer uptake was measured as standardized uptake values (SUV) for both tracers. In patients with multiple findings, ten bone lesions with highest SUV(max) were selected from which identical lesions from both scans were considered for direct comparison of SUV(max). Soft tissue findings of local and lymph node lesions from CE-CT were compared with PSMA PET/CT. RESULTS: Both scans were negative for bone lesions in 7 patients (25%). Of 699 lesions consistent with skeletal metastasis in 21 patients on fluoride PET/CT, PSMA PET/CT identified 579 lesions (83%). In 69 identical bone lesions fluoride PET/CT showed significantly higher uptake (mean SUV(max): 73.1 ± 36.8) compared to PSMA PET/CT (34.5 ± 31.4; p < 0.001). Compared to CE-CT, PSMA PET/CT showed better diagnostic performance in locating local (96% vs 61%, p = 0.004) and lymph node (94% vs 46%, p < 0.001) metastasis. CONCLUSION: In this prospective comparative study, PSMA PET/CT detected the majority of bone lesions that were positive on fluoride PET/CT. Further, this study indicates better diagnostic performance of PSMA PET/CT to locate soft tissue lesions compared to CE-CT. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41824-022-00127-4.
format Online
Article
Text
id pubmed-8885936
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-88859362022-03-08 Comparison of (68)Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer Regula, Naresh Kostaras, Vasileios Johansson, Silvia Trampal, Carlos Lindström, Elin Lubberink, Mark Iyer, Victor Velikyan, Irina Sörensen, Jens Eur J Hybrid Imaging Original Article BACKGROUND: (18)F-NaF positron emission tomography/computed tomography (fluoride PET/CT) is considered the most sensitive technique to detect bone metastasis in prostate cancer (PCa). (68)Ga-PSMA-11 (PSMA) PET/CT is increasingly used for staging of PCa. This study primarily aimed to compare the diagnostic performance of fluoride PET/CT and gallium-based PSMA PET/CT in identifying bone metastasis followed by a comparison of PSMA PET/CT with contrast-enhanced CT (CE-CT) in identifying soft tissue lesions as a secondary objective. METHODS: Twenty-eight PCa patients with high suspicion of disseminated disease following curative treatment were prospectively evaluated. PET/CT examinations using fluoride and PSMA were performed. All suspicious bone lesions were counted, and the tracer uptake was measured as standardized uptake values (SUV) for both tracers. In patients with multiple findings, ten bone lesions with highest SUV(max) were selected from which identical lesions from both scans were considered for direct comparison of SUV(max). Soft tissue findings of local and lymph node lesions from CE-CT were compared with PSMA PET/CT. RESULTS: Both scans were negative for bone lesions in 7 patients (25%). Of 699 lesions consistent with skeletal metastasis in 21 patients on fluoride PET/CT, PSMA PET/CT identified 579 lesions (83%). In 69 identical bone lesions fluoride PET/CT showed significantly higher uptake (mean SUV(max): 73.1 ± 36.8) compared to PSMA PET/CT (34.5 ± 31.4; p < 0.001). Compared to CE-CT, PSMA PET/CT showed better diagnostic performance in locating local (96% vs 61%, p = 0.004) and lymph node (94% vs 46%, p < 0.001) metastasis. CONCLUSION: In this prospective comparative study, PSMA PET/CT detected the majority of bone lesions that were positive on fluoride PET/CT. Further, this study indicates better diagnostic performance of PSMA PET/CT to locate soft tissue lesions compared to CE-CT. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41824-022-00127-4. Springer International Publishing 2022-03-01 /pmc/articles/PMC8885936/ /pubmed/35229224 http://dx.doi.org/10.1186/s41824-022-00127-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Regula, Naresh
Kostaras, Vasileios
Johansson, Silvia
Trampal, Carlos
Lindström, Elin
Lubberink, Mark
Iyer, Victor
Velikyan, Irina
Sörensen, Jens
Comparison of (68)Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer
title Comparison of (68)Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer
title_full Comparison of (68)Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer
title_fullStr Comparison of (68)Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer
title_full_unstemmed Comparison of (68)Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer
title_short Comparison of (68)Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer
title_sort comparison of (68)ga-psma pet/ct with fluoride pet/ct for detection of bone metastatic disease in prostate cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885936/
https://www.ncbi.nlm.nih.gov/pubmed/35229224
http://dx.doi.org/10.1186/s41824-022-00127-4
work_keys_str_mv AT regulanaresh comparisonof68gapsmapetctwithfluoridepetctfordetectionofbonemetastaticdiseaseinprostatecancer
AT kostarasvasileios comparisonof68gapsmapetctwithfluoridepetctfordetectionofbonemetastaticdiseaseinprostatecancer
AT johanssonsilvia comparisonof68gapsmapetctwithfluoridepetctfordetectionofbonemetastaticdiseaseinprostatecancer
AT trampalcarlos comparisonof68gapsmapetctwithfluoridepetctfordetectionofbonemetastaticdiseaseinprostatecancer
AT lindstromelin comparisonof68gapsmapetctwithfluoridepetctfordetectionofbonemetastaticdiseaseinprostatecancer
AT lubberinkmark comparisonof68gapsmapetctwithfluoridepetctfordetectionofbonemetastaticdiseaseinprostatecancer
AT iyervictor comparisonof68gapsmapetctwithfluoridepetctfordetectionofbonemetastaticdiseaseinprostatecancer
AT velikyanirina comparisonof68gapsmapetctwithfluoridepetctfordetectionofbonemetastaticdiseaseinprostatecancer
AT sorensenjens comparisonof68gapsmapetctwithfluoridepetctfordetectionofbonemetastaticdiseaseinprostatecancer